{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doravirine+100+Mg", "query": { "intervention": "Doravirine 100 Mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doravirine+100+Mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T06:55:08.692Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05631093", "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ART", "type": "DRUG" }, { "name": "DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 553, "start_date": "2023-02-20", "completion_date": "2028-07-11", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 15, "location_summary": "Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05631093" }, { "nct_id": "NCT04820933", "title": "Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV I Infection", "Cardiovascular Risk Factor", "Lipid Metabolism Disorders" ], "interventions": [ { "name": "Doravirine 100 Mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "18 Years to 70 Years · Male only" }, "enrollment_count": 26, "start_date": "2024-03-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04820933" }, { "nct_id": "NCT05705349", "title": "DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to DOR/ISL", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 537, "start_date": "2023-03-08", "completion_date": "2029-08-05", "has_results": false, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705349" }, { "nct_id": "NCT05630755", "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2023-02-17", "completion_date": "2028-08-04", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630755" }, { "nct_id": "NCT03272347", "title": "Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Placebo to Islatravir", "type": "DRUG" }, { "name": "Doravirine", "type": "DRUG" }, { "name": "Placebo to Doravirine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Placebo to Lamivudine", "type": "DRUG" }, { "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate", "type": "DRUG" }, { "name": "Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate", "type": "DRUG" }, { "name": "Doravirine/Islatravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2017-11-27", "completion_date": "2022-03-09", "has_results": true, "last_update_posted_date": "2023-03-29", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03272347" }, { "nct_id": "NCT04223791", "title": "Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to FDC DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 643, "start_date": "2020-02-18", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04223791" }, { "nct_id": "NCT05457530", "title": "Doravirine and Weight Gain in Antiretroviral Naive", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Body Weight Changes", "Human Immunodeficiency Virus", "ART", "Obesity", "Minority Health", "BMD", "Metabolic Syndrome", "Fasting" ], "interventions": [ { "name": "DOR/3TC/TDF", "type": "DRUG" }, { "name": "DOR + FTC/TAF", "type": "COMBINATION_PRODUCT" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Prism Health North Texas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2022-08-01", "completion_date": "2023-05-03", "has_results": false, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457530" }, { "nct_id": "NCT06719570", "title": "A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MK-8591A", "type": "DRUG" }, { "name": "Islatravir", "type": "DRUG" }, { "name": "Doravine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2024-01-23", "completion_date": "2024-03-15", "has_results": false, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06719570" }, { "nct_id": "NCT04518228", "title": "Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV", "Tuberculosis" ], "interventions": [ { "name": "Bictegravir (BIC)", "type": "DRUG" }, { "name": "Tenofovir alafenamide (TAF)", "type": "DRUG" }, { "name": "Long-acting injectable formulation of cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Atazanavir/ritonavir (ATV/r)", "type": "DRUG" }, { "name": "Darunavir/ritonavir (DRV/r)", "type": "DRUG" }, { "name": "Lopinavir/ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "First-Line TB Treatment", "type": "DRUG" }, { "name": "Second-Line TB Treatment", "type": "DRUG" }, { "name": "Doravirine (DOR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 205, "start_date": "2021-09-01", "completion_date": "2025-07-10", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 13, "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518228" }, { "nct_id": "NCT04233216", "title": "Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "DOR", "type": "DRUG" }, { "name": "DOR/ISL", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" }, { "name": "Placebo to DOR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "2020-03-18", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-28T06:55:08.692Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233216" } ] }